发布求助
文献互助 智能选刊 最新文献

Leukemia & Lymphoma最新文献

筛选
英文 中文
Clinical trials in early-stage CLL: what has been learned and what's next? 早期CLL的临床试验：已经学到了什么？下一步是什么？
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-29 DOI: 10.1080/10428194.2024.2422839
Manuela A Hoechstetter, Clemens-Martin Wendtner
{"title":"Clinical trials in early-stage CLL: what has been learned and what's next?","authors":"Manuela A Hoechstetter, Clemens-Martin Wendtner","doi":"10.1080/10428194.2024.2422839","DOIUrl":"10.1080/10428194.2024.2422839","url":null,"abstract":"<p><p>More than 80% of newly diagnosed chronic lymphocytic leukemia (CLL) patients present with asymptomatic, early-stage CLL. Of these, only 30-50% progress to advanced stage with reduced survival, while the rest may never require treatment. According to the 2018 International Workshop on CLL (iwCLL) guidelines, patients who do not meet the criteria for treatment initiation should only be treated within the context of clinical trials, as data demonstrating an overall survival benefit in early-stage CLL are still awaited. Risk stratification through continually advancing prognostic models can assist in identifying high-risk patients for early, risk-adapted treatment within clinical trials. Currently, new targeted therapies with high efficacy and lower toxicity are available in early intervention trials. This review (1) explores the development of prognostic models for identifying high-risk patients, (2) examines the design of early intervention trial, (3) summarizes the outcomes of early intervention trials, particularly in the context of targeted therapies, and (4) highlights ongoing clinical trials involving targeted treatments.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"378-388"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ixazomib-induced thrombotic microangiopathy resolving without complement pathway inhibition: a case report. 伊沙佐米诱发的血栓性微血管病无需补体途径抑制即可缓解：一份病例报告。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-20 DOI: 10.1080/10428194.2024.2428360
Tanguy Lafont, Stephen Booth, Harry Wakefield
{"title":"Ixazomib-induced thrombotic microangiopathy resolving without complement pathway inhibition: a case report.","authors":"Tanguy Lafont, Stephen Booth, Harry Wakefield","doi":"10.1080/10428194.2024.2428360","DOIUrl":"10.1080/10428194.2024.2428360","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"569-571"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. 利妥昔单抗对新诊断费城染色体阳性急性淋巴细胞白血病的影响
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-12-01 DOI: 10.1080/10428194.2024.2432582
Fausto Alfredo Rios-Olais, Sergio Rodriguez-Rodriguez, Analy Mora-Cañas, Christian Omar Ramos-Peñafiel, Victor Itaí Urbalejo-Ceniceros, Yadith Karina Lopez-Garcia, Andres Gomez-De Leon, Nancy Delgado-Lopez, Mistral Castellanos-Mares, Patricia Carolina Figueroa-Hernandez, Roberta Demichelis-Gomez
{"title":"Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.","authors":"Fausto Alfredo Rios-Olais, Sergio Rodriguez-Rodriguez, Analy Mora-Cañas, Christian Omar Ramos-Peñafiel, Victor Itaí Urbalejo-Ceniceros, Yadith Karina Lopez-Garcia, Andres Gomez-De Leon, Nancy Delgado-Lopez, Mistral Castellanos-Mares, Patricia Carolina Figueroa-Hernandez, Roberta Demichelis-Gomez","doi":"10.1080/10428194.2024.2432582","DOIUrl":"10.1080/10428194.2024.2432582","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"561-564"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcomes of patients diagnosed with SETBP1 mutated myeloid neoplasms. 确诊为 SETBP1 基因突变骨髓性肿瘤患者的临床疗效。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-06 DOI: 10.1080/10428194.2024.2425048
Yazan Jabban, Mahmoud Yacout, Anmol Baranwal, Rong He, David Viswanatha, Patricia Greipp, Dragan Jevremovic, Kurt Bessonen, James Foran, Jeanne Palmer, Antoine N Saliba, Mehrdad Hefazi-Torghabeh, Kebede Begna, William J Hogan, Abhishek Mangaonkar, Mrinal Patnaik, Mithun Shah, Hassan Alkhateeb, Aref Al-Kali
{"title":"Clinical outcomes of patients diagnosed with <i>SETBP1</i> mutated myeloid neoplasms.","authors":"Yazan Jabban, Mahmoud Yacout, Anmol Baranwal, Rong He, David Viswanatha, Patricia Greipp, Dragan Jevremovic, Kurt Bessonen, James Foran, Jeanne Palmer, Antoine N Saliba, Mehrdad Hefazi-Torghabeh, Kebede Begna, William J Hogan, Abhishek Mangaonkar, Mrinal Patnaik, Mithun Shah, Hassan Alkhateeb, Aref Al-Kali","doi":"10.1080/10428194.2024.2425048","DOIUrl":"10.1080/10428194.2024.2425048","url":null,"abstract":"<p><p>SETBP1 mutations (m) have been previously reported in myeloid neoplasms and are associated with poor prognostic co-mutations and cytogenetic abnormalities. We retrospectively analyzed the charts of 113 patients diagnosed with myeloid neoplasms with SETBP1m. The most common diagnosis was MDS (31%). Cytogenetics were abnormal in 51 cases (46.4%), with monosomy 7 being the most common (41.1%). The most frequent co-mutations were ASXL1 (71.7%), SRSF2 (46.9%), TET2 (20.4%). Higher SETBP1m VAF was associated with proliferative features (<i>p</i> < 0.05). Most SETBP1m (96.5%) were in one of three hotspots (Asp868, Gly870, Ile871), with Asp868m being most frequent (51.3%). Patients with Ile871m had higher number of co-mutations (median= 4) compared to Asp868m and Gly870m (<i>p</i> = 0.07). On multivariate analysis, age ≥ 70 years (<i>p</i> = 0.004) and higher peripheral blood blasts (<i>p</i> = 0.02) had worse OS. Patients with Ile871m had lower OS when compared with Asp868m and Gly870m (5.5 months vs. 17.4 and 17 months, respectively, <i>p</i> = 0.1).</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"497-506"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and biological advances of critical complications in acute myeloid leukemia. 急性髓性白血病严重并发症的临床和生物学进展。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-24 DOI: 10.1080/10428194.2024.2425051
Alessandro Costa, Emilia Scalzulli, Ida Carmosino, Claudia Ielo, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia
{"title":"Clinical and biological advances of critical complications in acute myeloid leukemia.","authors":"Alessandro Costa, Emilia Scalzulli, Ida Carmosino, Claudia Ielo, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia","doi":"10.1080/10428194.2024.2425051","DOIUrl":"10.1080/10428194.2024.2425051","url":null,"abstract":"<p><p>Managing acute myeloid leukemia (AML) and its critical complications requires understanding the complex interplay between disease biology, treatment strategies, and patient characteristics. Complications like sepsis, acute respiratory failure (ARF), hyperleukocytosis, coagulopathy, tumor lysis syndrome (TLS) and central nervous system (CNS) involvement present unique challenges needing precise evaluation and tailored interventions. Venetoclax-induced TLS and differentiation syndrome (DS) from IDH1/IDH2 or menin inhibitors highlight the need for ongoing research and innovative approaches. As the microbiological landscape evolves and new therapeutic agents emerge, adapting strategies to mitigate harmful pharmacological interactions is crucial. Advances in understanding the genetic profiles of patients with hyperleukocytosis contribute to better-targeted therapeutic strategies. Effective AML management relies on collaborative efforts from hematologists, specialized services, and intensive care units (ICUs). This review analyzes recent data on critical AML complications, identifies areas for further investigation, and proposes ways to advance clinical research and enhance patient care strategies.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"400-419"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia. 强化化疗后口服阿扎胞苷维持治疗与 Venetoclax 和阿扎胞苷：新诊断急性髓性白血病的实际疗效。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-28 DOI: 10.1080/10428194.2024.2425792
Alice Mims, Zhuoer Xie, Ravi Potluri, David Rotter, Manoj Chevli, Thomas Prebet, Lona Gaugler, Maria Strocchia, Alberto Vasconcelos, Jan Sieluk
{"title":"Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia.","authors":"Alice Mims, Zhuoer Xie, Ravi Potluri, David Rotter, Manoj Chevli, Thomas Prebet, Lona Gaugler, Maria Strocchia, Alberto Vasconcelos, Jan Sieluk","doi":"10.1080/10428194.2024.2425792","DOIUrl":"10.1080/10428194.2024.2425792","url":null,"abstract":"<p><p>Oral azacitidine (Oral-AZA) is recommended as maintenance therapy for patients with newly diagnosed acute myeloid leukemia (ND AML) achieving remission with intensive chemotherapy (IC) but not transplant candidates; venetoclax plus injectable azacitidine (VEN-AZA) is recommended for patients ineligible for IC. Some patients may be considered candidates for either regimen. This retrospective study used Flatiron Health's database to compare treatment patterns and clinical outcomes with Oral-AZA maintenance after IC (IC🡪Oral-AZA) versus frontline VEN-AZA. Relapse-free survival (RFS) and overall survival (OS) were analyzed at 4 different time points, including from Oral-AZA initiation (IC🡪Oral-AZA cohort) or from remission (VEN-AZA cohort) in the Core Analysis. Median RFS was 14.9 and 8.1 months for IC🡪Oral-AZA and VEN-AZA propensity score-matched cohorts, in the Core Analysis (<i>n</i> = 32 in each; <i>p</i> = 0.027); median OS was 18.7 and 15.2 months (<i>p</i> = 0.034). In patients with AML, IC🡪Oral-AZA significantly improved RFS and OS compared with VEN-AZA.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"479-487"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extramedullary immunoprivileged sites as a niche for residual and relapsed FLT3-ITD mutated AML: an unmet clinical need. 髓外免疫特权位点作为残留和复发的FLT3-ITD突变AML的利基：未满足的临床需求。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-28 DOI: 10.1080/10428194.2024.2431880
Philip D Tracy, Ruben Delgado, Ahmad Al-Akdi, Monika Pilichowska, Zheng Zhou
{"title":"Extramedullary immunoprivileged sites as a niche for residual and relapsed <i>FLT3-</i>ITD mutated AML: an unmet clinical need.","authors":"Philip D Tracy, Ruben Delgado, Ahmad Al-Akdi, Monika Pilichowska, Zheng Zhou","doi":"10.1080/10428194.2024.2431880","DOIUrl":"10.1080/10428194.2024.2431880","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"548-552"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of acute macular neuroretinopathy as atipycal ICANS manifestation after CAR-T cell infusion. CAR-T细胞输注后急性黄斑神经视网膜病变非典型ICANS表现1例。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-12 DOI: 10.1080/10428194.2024.2426056
A Soravia, F Menchini, F Di Bin, G Facchin, P Lanzetta, R Fanin, F Patriarca
{"title":"A case of acute macular neuroretinopathy as atipycal ICANS manifestation after CAR-T cell infusion.","authors":"A Soravia, F Menchini, F Di Bin, G Facchin, P Lanzetta, R Fanin, F Patriarca","doi":"10.1080/10428194.2024.2426056","DOIUrl":"10.1080/10428194.2024.2426056","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"565-566"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma. 大 B 细胞淋巴瘤患者使用免疫检查点抑制剂后，CAR T 细胞毒性严重，但可长期存活。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-20 DOI: 10.1080/10428194.2024.2430703
Xavier Deschênes-Simard, Martina Pennisi, Miguel-Angel Perales, Gunjan L Shah, Andrew D Zelenetz, Joachim Yahalom, Brandon S Imber, Bianca D Santomasso, Parastoo B Dahi
{"title":"Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma.","authors":"Xavier Deschênes-Simard, Martina Pennisi, Miguel-Angel Perales, Gunjan L Shah, Andrew D Zelenetz, Joachim Yahalom, Brandon S Imber, Bianca D Santomasso, Parastoo B Dahi","doi":"10.1080/10428194.2024.2430703","DOIUrl":"10.1080/10428194.2024.2430703","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"535-540"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11850207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience. 急性早幼粒细胞白血病患者的三氧化二砷神经毒性：单中心经验。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-03-01 Epub Date: 2024-11-08 DOI: 10.1080/10428194.2024.2427266
G Arrigo, M Scaldaferri, E Audisio, E Boscaro, F Catania, F Cattel, L Celona, M Cerrano, R Freilone, V Giai, I Urbino, S D'Ardia, C Frairia
{"title":"Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience.","authors":"G Arrigo, M Scaldaferri, E Audisio, E Boscaro, F Catania, F Cattel, L Celona, M Cerrano, R Freilone, V Giai, I Urbino, S D'Ardia, C Frairia","doi":"10.1080/10428194.2024.2427266","DOIUrl":"10.1080/10428194.2024.2427266","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"567-568"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信